Science Current Events | Science News | Brightsurf.com
 

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute


Related Tamoxifen Current Events and Tamoxifen News Articles


Two known chemotherapy agents effectively target breast cancer stem cells
Two existing chemotherapy drugs appear to be a powerful pair in targeting errant stem cells that are making breast cancer and enabling its spread and recurrence, scientists report.

What factors affect non-compliance with endocrine therapy among young women with breast cancer?
A new study from Harvard Medical School of young women with hormone receptor-positive (HR+) breast cancer showed that more than half did not believe endocrine therapy was essential, even though it has been proven to reduce recurrence and improve survival.

Recommendation to omit radiation therapy after lumpectomy is not frequently implemented
Nearly two thirds of U.S. women age 70 or older with stage I breast cancer1 who undergo lumpectomy and are eligible to safely omit subsequent radiation therapy (RT) according to national cancer guidelines still receive this treatment, according to new study results.

From tamoxifen to dendrogenin A: Discovery of a mammalian tumor suppressor metabolite
Researchers from the Cancer Research Center of Toulouse have conducted the first comprehensive review on dendrogenin A (DDA).

Why does tamoxifen work better in some women?
The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects.

Five out of six women at higher risk reject drugs to prevent breast cancer
Cancer Research UK scientists have found that five in six women with increased risk of breast cancer turn down drugs likely to prevent the disease, according to research published in Annals of Oncology.

Aspirin use does not improve outcomes for cancer patients, but may lower breast density
Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question.

Denosumab improves disease-free survival for postmenopausal patients w HR+ breast cancer
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

Taking antidepressants with cancer drug does not increase breast-cancer recurrence
A large study of patients with breast cancer who took the anti-cancer drug tamoxifen while taking an antidepressant were not found to have an increased risk of recurrence. The Kaiser Permanente study was published today in The Journal of the National Cancer Institute.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)


Tamoxifen is one of the most widely prescribed drugs used to prevent the recurrence of breast cancer. A nonsteroidal antiestrogen, it has been successful in treating postmenopausal women at nearly all stages of breast cancer. Despite its popularity, disturbing questions remain about the use of this drug. How effective is tamoxifen in treating patients who have hormone-insensitive breast tumors or who have not yet reached menopause? What are the potential risks in taking tamoxifen, and do they ever outweigh its benefits? Should tamoxifen be administered as a prophylactic drug for healthy premenopausal women who are at high risk of developing breast cancer?

In this vitally important book, two leading scientific investigators present a balanced and accessible discussion of the...

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Philipp Y. Maximov (Author), Russell E. McDaniel (Author), V. Craig Jordan (Author)


Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by Birkhäuser


Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
by Cali Press (Author)


Lymph node (LN) status is the most important prognostic variable used to guide ER positive (+) breast cancer treatment. While a positive nodal status is traditionally associated with a poor prognosis, a subset of these patients respond well to treatment and achieve long-term survival. Several gene signatures have been established as a means of predicting outcome of breast cancer patients, but the development and indication for use of these assays varies. Here we compare the capacity of two approved gene signatures and a third novel signature to predict outcome in distinct LN negative (-) and LN+ populations. We also examine biological differences between tumours associated with LN- and LN+ disease. Proceeds from the sale of this book go to support an elderly disabled person.

Tamoxifen And Breast Cancer - Scholar's Choice Edition

Tamoxifen And Breast Cancer - Scholar's Choice Edition
by United States Congress Senate Committee (Creator)



This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work was reproduced from the original artifact, and remains as true to the original work as possible. Therefore, you will see the original copyright references, library stamps (as most of these works have been housed in our most important libraries around the world), and other notations in the work.

This work is in the public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work.

As a reproduction of a historical artifact, this work may contain missing or...

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)
by Laura Bertolaso (Author)


Il tamoxifen è un farmaco ampiamente usato per il trattamento e la prevenzione del più frequente istotipo di tumore mammario, quello positivo per i recettori degli estrogeni. Nonostante i notevoli successi nella pratica clinica derivanti dall'impiego di tale farmaco, essi non riguardano ancora la totalità delle pazienti. Questo libro espone i promettenti seppur preliminari risultati di uno studio iniziato nel 2010 volto ad analizzare sperimentalmente i fattori molecolari e genetici a potenziale carattere predittivo nella determinazione della risposta terapeutica.

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by John A. Kellen (Author)


Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated...

Tamoxifen: A Guide for Clinicians and Patients

Tamoxifen: A Guide for Clinicians and Patients
by Northwestern Univ. Medical School V. Craig Jordan (Editor)




Tamoxifen: New Hope in the Fight Against Breast Cancer

Tamoxifen: New Hope in the Fight Against Breast Cancer
by John F. Kessler (Author), Greg A. Annussek (Author)


On the market in the United States since 1978, tamoxifen is the most widely prescribed anti-cancer drug in the world. Recently, this powerful cancer fighter has been found to prevent breast cancer, and its use as a breast cancer preventive has been approved by the FDA. For women at high risk of breast cancer, tamoxifen provides a new option for prevention of this disease. Now, in this comprehensive, accessible guide, a medical doctor provides answers to the critical questions every woman should ask before considering preventive therapy or cancer treatment with tamoxifen.Should I consider myself at high risk of breast cancer?
Do the risks of breast cancer outweight the risks of taking tamoxifen?
How does tamoxifen compare with other prevention therapies?
What are the side...

Tamoxifen for the Treatment and Prevention of Breast Cancer

Tamoxifen for the Treatment and Prevention of Breast Cancer
by V. Craig Jordan PhD. DSC. (Author)


Dr. V. Craig Jordan's conversations with hundreds of women with breast cancer and his passion to help find a cure for the disease have compelled him to gather eminent cancer specialists to contribute to this book. Distinguished physicians, scientists, breast cancer advocates, and breast cancer survivors have assembled here to answer numerous questions about tamoxifen. Written for both the clinician and patient, this book is a premier source of information about the world's leading drug for the treatment and prevention of breast cancer.

© 2017 BrightSurf.com